A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

223

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Follicular Lymphoma
Richter Transformation Lymphoma

Interventions

BIOLOGICAL: Zilovertamab vedotin
DRUG: Nemtabrutinib

Sponsor

Merck Sharp & Dohme LLC